ProfileGDS5678 / 1425378_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 45% 44% 45% 44% 45% 43% 44% 44% 45% 44% 45% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1717748
GSM967853U87-EV human glioblastoma xenograft - Control 23.0379745
GSM967854U87-EV human glioblastoma xenograft - Control 33.035944
GSM967855U87-EV human glioblastoma xenograft - Control 42.9907245
GSM967856U87-EV human glioblastoma xenograft - Control 52.9757444
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.145545
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0730143
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0109844
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0015144
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0217745
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0202644
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0111945
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0304744
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0272444